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Abstract
Background: Healthcare decisions are ideally based on clinical trial results, published in study registries, as journal
articles or summarized in secondary research articles. In this research project, we investigated the impact of
academically and commercially sponsored clinical trials on medical practice by measuring the proportion of trials
published and cited by systematic reviews and clinical guidelines.
Methods: We examined 691 multicenter, randomized controlled trials that started in 2005 or later and were
completed by the end of 2016. To determine whether sponsorship/funding and place of conduct influence a trial’s
impact, we created four sub-cohorts of investigator initiated trials (IITs) and industry sponsored trials (ISTs): 120 IITs
and 171 ISTs with German contribution compared to 200 IITs and 200 ISTs without German contribution. We
balanced the groups for study phase and place of conduct. German IITs were funded by the German Research
Foundation (DFG), the Federal Ministry of Education and Research (BMBF), or by another non-commercial research
organization. All other trials were drawn from the German Clinical Trials Register or ClinicalTrials.gov. We
investigated, to what extent study characteristics were associated with publication and impact using multivariable
logistic regressions.
Results: For 80% of the 691 trials, results were published as result articles in a medical journal and/or study registry,
52% were cited by a systematic review, and 26% reached impact in a clinical guideline. Drug trials and larger trials
were associated with a higher probability to be published and to have an impact than non-drug trials and smaller
trials. Results of IITs were more often published as a journal article while results of ISTs were more often published
in study registries. International ISTs less often gained impact by inclusion in systematic reviews or guidelines than
IITs.
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Conclusion: An encouraging high proportion of the clinical trials were published, and a considerable proportion
gained impact on clinical practice. However, there is still room for improvement. For publishing study results, study
registries have become an alternative or complement to journal articles, especially for ISTs. IITs funded by
governmental bodies in Germany reached an impact that is comparable to international IITs and ISTs.
Keywords: Randomized controlled trials as topic, Registries, Access to information, Evidence-based medicine,
Publishing, Systematic reviews as topic, Practice guidelines as topic, Knowledge translation, Health impact
assessment, Clinical decision-making
Background
Decisions in healthcare are ideally built on three pillars,
the experience of the clinician, the wishes and values of
the patient, and the best available external evidence, i.e.
results from clinical research [1]. Available, findable and
accessible clinical research results are mandatory for a
successful transfer of this knowledge into evidence-
based practice and further research [2]. Beside research
results, also information about detailed study methods is
important, since only they allow to appraise the validity,
reliability and applicability of clinical evidence to clinical
practice [3].
It has long been known that only a part of the clinical
studies conducted ultimately reach the stage of full pub-
lication in peer-reviewed journals [4]. For example, more
than half of the study results presented as an abstract at
scientific meetings fail to be published as a full-text art-
icle [5]. Thus, important study information cannot be
considered for health care decisions and further research
planning, which in turn could expose patients and future
study participants to unnecessary risks [6]. Systematic
reviews and meta-analyses can come to an erroneous
overall effect estimate and conclusion when unpublished
data cannot be considered [7]. If experiences and results
obtained from trials are not disseminated, they are not
only lost for health care, but also for further research.
Moreover, personnel resources and scarce research
funds are badly invested or even wasted.
An important step for increasing both, the transpar-
ency in research and the visibility of unpublished studies
was the implementation of study registries as well as the
call for prospective study registration by several research
organizations [8–10]. In Germany, funding organizations
such as the German Research Foundation (Deutsche
Forschungsgemeinschaft, DFG) and the Federal Ministry
of Education and Research (Bundesministerium für Bil-
dung und Forschung, BMBF) require the registration of
the trial in a public registry and publication of the trial
protocol following grant approval [11, 12]. Prospective
study registration is a major step forward, but it is
equally important to make the results of a trial publicly
available, which is possible through study registries.
However, even several years after these urgent calls for a
prospective study registration, there are still trials that
are not included in a study registry [13]. Thus, unpub-
lished studies and their results are difficult to identify.
In recent years, several authorities and research orga-
nizations became aware of the problems arising from
withholding study results. The World Health
Organization (WHO), the World Medical Association
(WMA) and the All Trials initiative [14], have alerted
that it is unethical to conduct human research without
subsequently publishing the results. They also pointed
out that vast financial resources spent on clinical re-
search are wasted when research results are not pub-
lished. Hence, these research organizations took various
steps to prevent incomplete, biased or non-reporting of
research results [15].
To the best of our knowledge, it is still unclear under
what conditions expenses are invested to support clinical
trials pay off in a way that the findings have an impact
on healthcare decisions. As an order of magnitude, in
2018 the German Research Foundation (DFG) alone
spent 22 Million euros for the conduction of 47 trials
within their clinical trials program [16]. Trial discontinu-
ation could be identified as one factor for non-
publication of clinical trials [17]. Another major step for-
ward would be to identify trial specific risk factors for
non-publication or for having no impact on medical
practice.
The aim of this project was to examine the transfer
process of clinical trial information into medical prac-
tice. First, we determined the proportion of the trials
that were published, the type (methods and/or results)
and place (as journal article, register entry) of published
information and the proportion of trials cited by second-
ary research articles (reviews and/or clinical guidelines).
We then analyzed whether there is an association of
pre-defined study characteristics (sponsoring/funding,
study phase, drug/non-drug intervention, number of
participants, number of primary outcome, medical field)
with publication or use by secondary research articles.
Methods
The rationale and design of this project is described in
detail in a previous publication [18].
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Study cohort
In brief, we set up a MS Access database consisting of
691 trials (hereafter referred to as study cohort). Eligible
for inclusion were clinical trials that were conducted at
multiple study sites, were randomized controlled (RCTs),
investigated drugs or non-drugs, started in 2005 or later
and were completed by the end of 2016. To find out
whether sponsorship/funding or place of conduct influ-
ence a trial’s impact, we created and compared sub-
cohorts of investigator initiated trials (IITs) and industry
sponsor trials (ISTs) with and without German contribu-
tion (Table 1). For the IIT-sub-cohort “Public Germany”
we included trials funded by the DFG and BMBF (Public
Germany gov), which we retrieved from the funder’s da-
tabases “German Project Information System” (GEPRIS)
of the DFG and the website of the BMBF [19, 20]. These
IITs served as basis for the determination of the eligibil-
ity criteria for the trials to be included in the comparison
sub-cohorts. The largest trial of the reference sub-cohort
included 4005 participants so that we only considered
trials up to this sample size for inclusion in the other
sub-cohorts. To achieve a reasonable number of German
IITs, we complemented the reference sub-cohort by an
equal number of IITs funded by other German non-
commercial organizations (Public Germany other),
which we randomly drew from the trials registries Clini-
calTrials.gov and German Clinical Trials Register
(DRKS) (Table 1). Trials included in the sub-cohort
Commercial Germany were also drawn from these two
registries, whereas trials included in the international
sub-cohorts (Public International and Commercial Inter-
national) were solely drawn from ClinicalTrials.gov.
To minimize possibly biasing study characteristics, we
aimed to generate comparable sub-cohorts by balancing
for effects of the study phase and the location of partici-
pating study sites (proportion of German study sites).
According to the distribution given in the sub-cohort
Public Germany, we balanced the three comparison sub-
cohorts Public International, Commercial Germany and
Commercial International for the study phase, of both
drug trials and non-drug trials, and the sub-cohort Com-
mercial Germany additionally for the proportion of Ger-
man study sites on all study sites (Table 1).
We independently double-extracted the pre-defined
study characteristics such as sample size, study phase,
number of pre-defined primary outcomes, and medical
fields [21] from the study registries, as we were inter-
ested in whether they were associated with research im-
pact. For further details concerning the project methods
please refer to the methods paper [18].
Identification of corresponding publications
For each trial, we identified related publications and
classified them according to the published trial
information: method article only (solely the study
methods are described in detail), result article only
(study results are described and usually the methods
very briefly), and both. This classification allowed us to
determine what kind of study information was used in
secondary research articles and clinical guidelines.
Search strategy: sources where journal articles were
identified
First, we searched for publications in different biomed-
ical databases and other sources using an incremental
search strategy (Additional file 2). As search terms, we
combined various study information such as the registry
identification number, study title, acronym, PICO-
aspects, and/or name of applicant or principal investiga-
tor. Searches for primary study reports were conducted
between 6 February 2018 and 30 August 2018. We then
downloaded the references of all identified published ar-
ticles into an Endnote database. We considered full arti-
cles reporting a trial’s methods and/or results. We also
downloaded all the study protocols we came across dur-
ing our literature search.
Trial information in study registries
Beside study registration, publishing trial results in study
registries is required since several years [14, 22, 23]. In
the DRKS, study related documents can be attached or
linked to the trial record. In ClinicalTrials.gov, results
can be entered directly into the trial record as a separate
register tab or are automatically searched and attached
by the study registries themselves [24].
In addition to the publication as a journal article, we
determined whether or not study information was avail-
able in study registries. Beside their registration in Clini-
cialTrials.gov and DRKS, 189 (27%) of the trials were
additionally registered in EudraCT and 35 (5%) in the
ISRCTN registry. Trials with results available in study
registries are hereafter referred to as “results in regis-
tries” [18].
Definition
Hereinafter, we use the following definitions: for publi-
cations in journal articles we use the expression “pub-
lished articles”. We distinguish between articles solely
concerning a trial’s methods, called “method articles”,
and articles also reporting study results (“result articles”).
Beside publication as journal article, results can be pub-
lished in study registries; in this case, we use the expres-
sion “results in registries”. For published trial results, i.e.
as result article or as results in registries, we use the gen-
eral term “published results”.
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Total 60 60 120 (100) 200 (100) 171 (100) 200 (100) 691 (100)
Registered ina
ClinicalTrials.gov
32 (53) 16 (27) 48 (40) 200 (100) 158 (92) 200 (100) 606 (88)
DRKSb 14 (23) 48 (80) 62 (52) – 19 (11) – 81 (12)
ISRCTNc 27 (45) 5 (8) 32 (27) 3 (1) – – 35 (5)
EudraCTd 40 (67) 10 (17) 50 (42) 18 (9) 88 (52) 33 (17) 189 (27)
Study status
Completed 43 (72) 59 (98) 102 (85) 200 (100) 170 (100) 200 (100) 672 (97)
Prematurely
ended
12 (20) 1 (2) 13 (11) 1 (< 1) 14 (2)
Still ongoinge 5 (8) – 5 (4) 5 (< 1)
Collaboration
International 19 (32) 7 (12) 26 (22) 44 (22) 71 (42) 69 (35) 210 (30)
National 40 (66) 53 (88) 93 (78) 156 (78) 100 (58) 131 (65) 479 (69)
Unclear 1 (2) – 1 (< 1) – – – 2 (< 1)
Study size (Median = 150)
> 150 46 (76) 28 (47) 74 (62) 81 (40) 74 (43) 115 (58) 344 (50)
≤ 150 13 (22) 32 (53) 45 (38) 119 (60) 97 (57) 85 (42) 346 (50)
Unclear 1 (2) – 1 (< 1) – – – 1 (< 1)
Number of primary outcome(s)
0 – – – – 1 (1) – 1 (< 1)
1 44 (73) 44 (73) 88 (73) 152 (76) 122 (71) 133 (67) 495 (72)
> 1 (range 2–
36)
16 (27) 16 (27) 32 (27) 48 (24) 48 (28) 67 (33) 195 (28)
Study phase drug trialsf
Total 41 (68) 15 (25) 56 (47) 93 (47) 93 (54) 93 (47) 335 (48)
2 9 (15) 5 (8) 14 (12) 23 (12) 23 (13) 23 (12) 83 (12)
3 20 (33) 7 (12) 27 (22) 45 (23) 45 (26) 45 (23) 162 (23)
4 12 (20) 3 (5) 15 (13) 25 (13) 25 (15) 25 (13) 90 (13)
Study phase non-drug trialsg
Total 19 (32) 45 (75) 64 (53) 107 (53) 78 (46) 107 (53) 356 (52)
A – 9 (15) 9 (7) 15 (7) 11 (7) 15 (7) 50 (7)
B 16 (27) 33 (55) 49 (41) 82 (41) 43 (25) 82 (41) 256 (37)
C 3 (5) 3 (5) 6 (5) 10 (5) 24 (14) 10 (5) 50 (7)
a Several trials were registered in more than one trials registry, i.e. numbers do not sum up to the total numbers (100%); bDRKS: German Clinical Trials Register;
cISRCTN: International Standard Randomized Controlled Trials Number registry; dEudraCT: European Union Drug Regulating Authorities Clinical Trials Database;
eStatus as of 24 April 2020; f15 drug trials of phase 2–3 were counted as phase 2; 24 non-drug trials of phase A-B were counted as phase A; gIn the sub-cohort
“Commercial Germany”, we included all non-drug trials available in the study registries, resulting in slightly differing distributions of study phases among the
4 sub-cohorts
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Identification of secondary research articles citing primary
published articles
To assess the research impact of the included trials, we
investigated whether or not published articles were cited
by secondary research articles, i.e. systematic reviews/
meta-analyses and clinical guidelines.
Systematic reviews
For each published article, we downloaded all references
listed under the functions “Cited by” in PubMed and
“Times Cited” in Web of Science. To identify the sys-
tematic reviews and meta-analyses among the citing arti-
cles, we matched their Digital Object Identifier (DOI)
with the record-DOIs included in the database Episte-
monikos, which can be considered as the “largest source
of systematic reviews relevant for health-decision mak-
ing” [25]. Epistemonikos includes references of four cat-
egories: broad syntheses, systematic reviews, structured
summaries and primary studies. In our project, we fo-
cused on references classified as systematic reviews or
broad syntheses. Both categories are hereinafter referred
to as “systematic reviews” (SRs).
If a DOI of a citing article was found in Epistemoni-
kos, the publication type was verified and the citing art-
icle labelled as systematic review. We then manually
assessed how the published articles were used and where
they were cited in the systematic reviews/meta-analyses:
 General information or methods of the published
article were used and cited in the systematic review,
e.g. in the introduction or discussion section,
 Study results reported in the published article were
included in the systematic review/meta-analyses or
 Study results reported in the published article were
not included in the systematic review/meta-analyses,
e. g. not meeting eligibility criteria.
Clinical guidelines
The ultimate step for a successful implementation of tri-
al’s results in medical practice is their inclusion in clin-
ical practice guidelines. To identify these, we manually
searched in the clinical guidelines databases TRIP [26],
NICE evidence search [27] and AWMF (Association of
the Scientific Medical Societies) [28]. We searched for
clinical guidelines citing the trial publications. As search
terms, we used (parts of) the title and the name of the
first author of the published articles as well as the corre-
sponding systematic review/meta-analysis; to identify
guidelines citing results published in registries, we
searched with the register identification number. The
search period for guidelines citing the published articles
was between December 2018 and March 2019, for
guidelines including systematic reviews between April
and August 2019, and for the registry identifier in
February 2020. For each identified clinical guideline, we
retrieved the full text and verified the citations.
Data collection
We extracted the following information about the publi-
cations into an Access database: 1) whether or not study
results were reported in study registries, 2) bibliographic
information of included publications and content
(method article or result article), 3) bibliographic infor-
mation of citing systematic reviews/meta-analyses, and
4) bibliographic information of citing guidelines.
Semi-automatic tool
Within this project, one author (KN) developed a semi-
automatic tool (called DoiScout) that facilitates large-
scale literature searches and citation analyses in order to
carry out extensive literature searches based on internet
search engines more time-efficiently.
DoiScout automatically identifies primary published
articles that reference a particular study registry ID (e.g.
NCT02179424). Bibliographic information about the
identified articles is extracted and presented in a list that
is formatted in a way that allows passing on the informa-
tion to other software programs for further processing.
A second feature refers to citation analysis. Search en-
gines behind platforms such as PubMed (www.pubmed.
gov) and Web of Science (www.webofknowledge.com)
can be used to identify other articles, e.g. primary re-
search articles, systematic reviews and clinical guidelines
that cite a given article. DoiScout extracts the biblio-
graphic information of the citing articles and provides it
to the user in a workable format. In addition, DoiScout
can be used to identify articles citing the citing articles
of the original source. This can be done for any pre-
specified citation depth, thus providing a comprehensive
overview of the extent of a project’s academic impact.
The program of the DOIScout and a manual describ-
ing the features in more detail are available via the
GitHub platform [29].
Data analysis
We used queries in MS Access 2010TM and tabulation
in Microsoft Excel 2010 to obtain standard descriptive
statistics. Multivariable logistic regression was used to
determine the association of study characteristics with
the probability of a trial to be published, cited by sys-
tematic reviews and included in guidelines. Based on the
reference sub-cohort Public Germany, it was carried out
for the other sub-cohorts, for study phase, number of
participants, and number of primary outcomes. For time
to publication, multivariable Cox regression was used to
account for study characteristics. For distinguishing be-
tween first publication in a journal or in a registry, a
competing risk model was used and Aalen-Johansen
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The term “published trials” is used when “method arti-
cles”, “result articles” or “results in registers” are avail-
able. Results of a trial can be published as “result article”
in a journal or as “results in registries”, while methods
are always published as “journal article”. We first de-
scribed the proportion of publication types for the total
cohort and then for the different sub-cohorts. If not
mentioned otherwise, all percentages of trials given for
the entire cohort are calculated on the basis of the in-
cluded 691 trials. Percentages given for the sub-cohorts
are based on the number of trials in each sub-cohort.
Minor differences in summed percentages derive from
rounding to full integer.
Proportion of published trials
For our whole cohort, 576 (83%) of the 691 trials in-
cluded were published as a method article or a result
article in a medical journal and/or the trial results were
made available in study registries; results were available
for 555 (80%) of the trials (Fig. 1). For 107 (19%) trials,
results were solely published in a registry.
Trials published as journal article
Cohort For 472 (68%) of our 691 trials, we identified
947 corresponding published journal articles (Table 2,
Additional file 3). Out of 448 (65%) trials, 843 result arti-
cles were published. For 100 (15%) trials, 104 method ar-
ticles, without presenting any trial results, were found.
For 372 (54%) trials, only a result article was available.
We found both, a method article as well as a result
article for 76 (11%) of the trials. For three trials with a
method article, results were published only in registries.
No results were published for 21 (3%) trials with a
method article, neither in a journal article nor in a
registry.
For 98% (438 of 448) of the trials with published re-
sults, the pre-defined primary outcome was reported in
the result article.
The publication frequency, i.e. the number of pub-
lished articles per trial, is shown in Additional file 4.
Many trials (284, 60%) were published solely in one jour-
nal article. In the remaining trials, multiple publication
was highly represented. For example, only 8% of the tri-
als generated 29% of the publications, resulting in an
average publication frequency of 7.0 (median 6) publica-
tions per trial.
Sub-cohorts For the sub-cohorts, the proportion of tri-
als published varied between 77 and 87% (Fig. 2). Com-
pared to the sub-cohort Public Germany (77%), the
probability of a trial to be published is higher for the
sub-cohorts Public International (87%), Commercial
Germany (86%) and Commercial International (82%)
(Table 2). The publication of results ranged between
63% for Public Germany (58% for Public Germany gov
and 67% Public Germany other) and 86% for Commer-
cial Germany.
Obvious differences exist between the sub-cohorts re-
garding the type of publication. IITs were more often
published as a journal article than ISTs (Table 2). Espe-
cially method articles were more present for IITs (Public
Germany 38%, Public International 21%) than for the
IST-sub-cohorts (Commercial Germany: 6%; Commer-
cial International: 2%). Compared to the German sub-
cohorts, results were more often published as a journal
article for Public International trials and less often for
Fig. 1 Proportion of published trials and type of publication for the whole cohort (n = 691). Please refer also to Table 2
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Commercial International trials. Looking at the number
of publications per trials, multiple publications were
more common in IITs (Germany: 33%, International:
32%) compared to ISTs (Germany: 17%, International
14%).
Trial information available in study registries
Cohort For 293 (42%) of the 691 included trials, at least
one reference to a corresponding journal article was re-
ported in the study registry and/or a link to the original
publication source or a database was provided. This
means that 62% (293 of 472) of all published journal ar-
ticles could be found in study registries (Table 2).
Information on results was available for 449 (65%) tri-
als. For 305 (44%) trials, results were directly included in
a study registry and for 276 (40%), a reference to a result
article was reported. For 132 (19%) trials, both sources
were present and for 144 (21%) solely a reference of a
result article.
Sub-cohorts The proportion of trials with a reference or
link to the journal article was with 58 and 52% higher in
the Public sub-cohorts than in the Commercial sub-
cohorts with 33 and 32% (Table 2). Results in registries
ranged between 4 and 67%. The proportion of IST with
results in registries was higher than for IITs.
For Public Germany, only 4% of the trials had results
in registries. This small percentage can be explained by
the fact that most of those trials derived from the DRKS
register (summarized data, see Table 2 for more details),
where results cannot directly be entered.
For the three other sub-cohorts, between 29 and 39%
of the trials have results published in both registries and



































Total trials 60 60 120 (100) 200 (100) 171 (100) 200 (100) 691 (100)
Proportion of published trials
Published 48 (80) 44 (73) 92 (77) 174 (87) 147 (86) 163 (82) 576 (83)
95% CI 68–88 60–84 68–84 82–91 80–91 75–87 80–86
Not published 12 (20) 16 (27) 28 (23) 26 (13) 24 (14) 37 (19) 115 (17)
Type of publication; trials published as
Journal article 48 (80) 42 (70) 90 (75) 169 (85) 113 (66) 100 (50) 472 (68)
95% CI 68–90 57–81 66–83 79–89 59–73 43–57 65–72
Method article 31 (52) 15 (25) 46 (38) 41 (21) 10 (6) 3 (2) 100 (15)
95% CI 38–65 15–38 30–48 15–27 3–11 0–4 12–17
Result article 34 (57) 38 (63) 72 (60) 163 (82) 113 (66) 100 (50) 448 (65)
95% CI 43–69 50–75 51–69 75–87 59–73 43–57 61–68
Results in registries 3 (5) 2 (3) 5 (4) 65 (33) 101 (59) 134 (67) 305 (44)
95% CI 1–14 0–12 1–10 26–40 51–67 60–74 40–48
Published results 35 (58) 40 (67) 75 (63) 170 (85) 147 (86) 163 (82) 555 (80)
Combinations
Result as article AND in
registries
2 (3) 0 2 (2) 58 (29) 67 (39) 71 (36) 198 (29)
Method AND Result article 17 (28) 11 (18) 28 (23) 35 (18) 10 (6) 3 (2) 76 (11)
Method article, no
published results
13 (22) 4 (7) 17 (14) 4 (2) 0 0 21 (3)
Trial information in registries
Publ. ref. total 35 (58) 35 (58) 70 (58) 104 (52) 56 (33) 63 (32) 293 (42)
95% CI 50–71 45–71 49–67 45–59 26–40 25–38 39–46
Publ. ref. of result article 27 (45) 30 (50) 57 (48) 102 (51) 55 (32) 62 (31) 276 (40)
95% CI 32–58 37–63 38–57 44–58 25–40 25–38 36–44
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as journal articles and for 20 and 32% of the commercial
sub-cohorts, results were solely available in registries.
Study characteristics associated with publication of results
The multivariable analysis confirmed our findings re-
garding publication probability for the sub-cohorts. It
also showed that additional study characteristics are as-
sociated with the probability to be published: drug trials
were published more often than non-drug trials, larger
trials more often than smaller trials and trials with more
than one primary outcome more often than trials with
one primary outcome (Additional file 6).
Each trial was allocated to one of 23 pre-defined med-
ical fields (Additional file 6). In our cohort, the median
number of trials per medical field was 25 and ranged be-
tween 2 (anaesthesiology) and 104 (surgery), the propor-
tion of trials published ranged between 87 and 25%.
Statistically significant differences were only found for
medical fields with a sufficient number of trials (≥ 39):
higher publication rates were found for neurology (87%)
and psychiatry/psychotherapy (84%), lower for surgery
(64%) and ophthalmology (25%). Due to the limited
number of trials per medical field, an analysis for signifi-
cant differences was not appropriate for the sub-cohorts.
Further details on publication and impact are presented
in the chapter “Overall impact”.
Time to publication
The median time to any publication as a journal article
or in a study registry, including method papers, was
4.07 years (95% CI: 3.79–4.33). If only counting result
papers, the median time was longer (4.67 years, 95% CI:
4.36–5.03). The median time for any type of article (in-
cluding method papers) to be published in a journal was
5.19 years (95% CI: 4.83–5.82); if only result articles were
counted, the median was 6.09 years (95% CI: 5.66–6.62).
We analyzed the time to first publication of study re-
sults in a journal or in a registry also in the framework
of a competing risk model. This was visualized as Aalen-
Johansen estimators in a stacked probability plot (Fig. 3).
The result shows that for the majority of studies (about
52%) the first publication was found in a journal, while
about 28% of studies were first published in a study
registry.
Compared to Public Germany trials, results were pub-
lished earlier for trials of the other sub-cohorts (Table 3,
Fig. 4). Furthermore, drug trials were published earlier
than non-drug trials and larger trials earlier than
smaller. In our cohort, we did not find an association of
time to publication with the number of primary out-
comes (1 or more than 1).
Multivariable analysis with estimated covariate effects
for sub-cohorts, type of intervention, study size, number
of primary outcomes. Hazard ratio with 95% confidence
intervals. The intercept stands for the combination of
IIT Public Germany, drug trial, n ≤ 150 and one primary
outcome.
Impact: proportion of trials included in systematic
reviews and guidelines
Systematic reviews
One measure of impact of a trial is the citation of their
journal articles by systematic reviews. In 2631 systematic
reviews, 599 of 947 (63%) published journal articles de-
riving from our trials were cited. Overall, we identified
3429 citations in the reviews, as reviews cited more than
one of our journal articles (Additional file 7).
Fig. 2 Proportion of published trials and type of publication per sub-cohort. Please also refer to Table 2
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Cohort The 599 articles cited by systematic reviews cor-
responded to trials (Table 4). Out of those, 27% were
cited by only one systematic review; 73% by more than
one. It is notable that 15% of the published articles were
cited by 10 or more systematic reviews (Additional file 8).
The median number of citing systematic review(s) per
trial was 4 (range 1 to 99; mean = 4.1).
Similar proportions were found for the subgroup of re-
sult articles (529 of 843; 63%) and the corresponding tri-
als (335; 48%). Of the 104 method articles, 70 (67%)
method articles corresponding to 70 (10%) trials were
cited by a systematic review.
We not only examined whether retrieved publications
were cited in systematic reviews but also how they were
used (excluded, included or used otherwise). As publica-
tions included in secondary research articles are more
likely to influence clinical practice than excluded publica-
tions, this analysis is important for the assessment of the
impact of trials. Of the citations in systematic reviews,
69% (2374 from 3429) were included and correspond to
45% (309 of 691) trials (Table 4), 6% (190 of 3429) were
excluded and 25% (865 of 3429) were used otherwise.
Nevertheless, 69 of the 87 trials with excluded publica-
tions in reviews had included publications in other re-
views. For the remaining 18 trials, only exclusions were
found. Frequently stated reasons for the exclusion of pub-
lications were that cohorts failed to meet the eligibility cri-
teria and did not report the data of interest.
Table 3 Time from study start to publication of results, either in a registry or journal
Covariates Hazard ratio 95% CI p-value
Intercept 1
IIT Public International 2.243 1.703–2.956 P < 0.001
IST Commercial Germany 2.343 1.770–3.112 P < 0.001
IST Commercial International 2.332 1.761–3.072 P < 0.001
Non-drug trials versus drug trials 0.838 0.707–0.992 P < 0.05
Study size: n > 150 versus n≤ 150 1.215 1.023–1.442 P < 0.05
Number of primary outcome(s): > 1 versus 1 1.141 0.939–1.387 n.s.
Fig. 3 Cumulative incidence functions (Aalen-Johansen estimates)
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Sub-cohorts For the public sub-cohorts and for Com-
mercial Germany, citation by systematic reviews ranged
between 52 and 63% and was higher than in Commercial
International with 38% (Fig. 5 and Table 4). This differ-
ence might be explained by the lower proportion of tri-
als published as journal articles in ISTs (compare Fig. 2).
Furthermore, a relevant proportion of articles cited by
systematic reviews were method articles, which were
rare in ISTs but mainly present in IITs.
Study characteristics associated with citation by systematic
review
The multivariable analysis confirmed the significantly
lower representation of Commercial International trials in
systematic reviews compared to the other sub-cohorts.
Both, the type of intervention and the number of primary
outcomes are not associated with the inclusion probabil-
ity, whereas larger trials are significantly more often in-
cluded in reviews than smaller trials (Additional file 9).
Fig. 4 Kaplan-Meier estimates of the cumulative distribution function for time to publication of results, grouped by sub-cohort
Table 4 Proportion of trials (n = 691) cited by systematic reviews per sub-cohort and type of publication

































Total trials 60 60 120 (100) 200 (100) 171 (100) 200 (100) 691
(100)
Trials in SR 41 (68) 30 (50) 71 (59) 125 (63) 89 (52) 75 (38) 360 (52)
95% CI 55–80 37–63 50–68 55–69 44–60 31–45 48–56
Trials with method article in
SR
25 (42) 7 (12) 32 (27) 31 (16) 5 (3) 2 (1) 70 (10)
Trials with method article only
in SR
12 (20) 4 (7) 16 (13) 8 (4) 1 (1) 0 25 (4)
Trials with result article in SR 29 (48) 26 (43) 55 (46) 117 (59) 88 (51) 75 (38) 335 (48)
95% CI 35–62 31–57 37–55 51–65 44–59 31–45 45–52
Trials with method AND result
article in SR
13 (22) 3 (5) 16 (13) 23 (12) 4 (2) 2 (1) 45 (7)
Use in SR
Trials included in SR 31 (52) 21 (35) 52 (43) 107 (54) 84 (49) 66 (33) 309 (45)
95% CI 38–65 23–48 34–53 46–61 41–57 27–40 41–48
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Trials included in clinical guidelines
Cohort We found 574 citations of 178 trials (26%) in
guidelines (Fig. 6). Some of the guidelines included in-
formation from several of our trials. These corresponded
to 427 unique guidelines. On average, each of our trials
was cited 3.2 times (574/178) in guidelines. This “guide-
line inclusion factor” ranged between 2.9 and 3.7 for the
sub-cohorts.
One trial can be included in one guideline via several
pathways, namely via a published article or via a system-
atic review. The following analysis shows via what publi-
cation type trials were included in guidelines: 69% (122
of 178) of the trials were included in 285 of 427 (67%)
different guidelines via the citation of 382 systematic re-
views. 58% (104 of 178) of the trials were included
directly in 226 of 427 (53%) different guidelines via the
citation of 262 result articles. In total, 93% (166 of 178)
of the inclusions in guidelines come from result articles
via a direct or indirect pathway. 6% (10 of 178) of the
trials were included in 12 of 427 (3%) different guide-
lines via citation of 12 method articles. 4% (7 of 178) of
the trials were included in 6 (2%) different guidelines via
citation of seven registry information (Table 5).
Sub-cohorts In Fig. 7 / Table 5 it is shown that for the
sub-cohorts the inclusion of trials in guidelines ranged
between 17 and 31%. For the subgroup Public Germany
gov, even 45% (27 of 60) of the trials were cited in guide-
lines. Compared to Public Germany trials, the propor-
tion of trials included in a guideline is similar to Public
International and Commercial Germany trials, whereas
Fig. 5 Proportion of trials cited by systematic reviews
Fig. 6 Proportion of trials cited by guidelines, shown by type of publication
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Table 5 Proportion of trials (n = 691) cited by clinical guidelines per sub-cohort and type of publication



































Total trials 60 60 120 (100) 200 (100) 171 (100) 200 (100) 691
(100)
Trials in guidelines 27 (45) 8 (13) 35 (29) 61 (31) 50 (29) 32 (16) 178 (26)
95% CI 32–58 6–25 21–38 24–37 23–37 11–22 23–29
Direct
Trials with method articles in
guideline
7 (12) 0 7 (6) 2 (1) 0 1 (< 1) 10 (1)
Trials with result articles in
guideline
19 (32) 4 (7) 23 (19) 36 (18) 27 (16) 18 (9) 104 (15)
Trials with register ID in
guidelines
3 (5) 0 3 (3) 2 (1) 2 (1) 0 7 (1)
Trials with any direct citation 25 (42) 4 (7) 29 (24) 38 (19) 29 (17) 18 (9) 114 (16)
Indirect
Trials in guidelines via review 16 (27) 8 (13) 24 (20) 43 (22) 35 (20) 20 (10) 122 (18)
Direct AND indirect
Trials in guidelines via review
AND result article
12 (20) 8 (13) 20 (17) 42 (21) 35 (20) 20 (10) 117 (17)
Direct: guidelines cite the original published article(s); Indirect: guidelines cite systematic review(s) that include the original published article(s)
Fig. 7 Proportion of trials with research impact per sub-cohort (n = 691). Trials included in a guideline via citation of a published article, of results
published in registries or of a systematic review citing the trial
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commercial International trials are less often included in
guidelines.
Study characteristics associated with inclusion in a
guideline
Similar to the inclusion in reviews, the multivariable
analysis confirmed a significantly lower representation of
Commercial International trials in guidelines compared
to the other sub-cohorts and demonstrated that type of
intervention and number of primary outcomes are not
associated with the inclusion in guidelines. Larger trials
are about twice as often included in guidelines than
smaller trials (Additional file 10).
Overall impact
Lifecycle of trials Figure 8 shows the fate of the trials
included in our cohort from registration to publication
and to their impact on clinical practice. During their life-
cycle from registration to impact in clinical practice, the
number of relevant trials decreases with each step. 17%
of the trials have no published results. Of the 576 (83%)
published trials, 15% (107 of 691) have their results only
published in registries and therefore might have less
awareness and a limited impact in the scientific
community.
Trials published as journal article(s) (472; 68%) have a
good chance to be cited in reviews or guidelines. Never-
theless, in our cohort, a relevant percentage did not find
an inclusion in clinical practice: only 309 (45%) of the
trials were included in systematic reviews and 178 (26%)
in guidelines.
Cohort Of all trials, 274 (40%) generated no impact: 115
(17%) of the trials were not published and of the pub-
lished trials, 160 (23%) were not cited by either a system-
atic review or a guideline (Fig. 9).
Used by secondary research articles were 417 (60%)
trials: 361 (52%) were cited by a systematic review, and
178 (26%) by a guideline. Out of those, 123 (18%) were
cited by both, a systematic review and a guideline. This
means that more than half (52%) of the trials were cited
in a systematic review and that about a quarter (26%)
reached an impact in a clinical guideline.
Sub-cohort Commercially funded trials, especially Com-
mercial International trials, less often gain an impact by
inclusion in systematic reviews (52%; 39% for SRs, and
29%; 31% for guidelines) than publicly sponsored trials
or guidelines (59%; 63% for SRs, and 29 and 17% for
guidelines). The distribution of the three “impact-pro-
portions” concerning inclusion in reviews and/or guide-
lines showed only minor differences between the sub-
cohorts (Fig. 10).
Medical fields
For our cohort, we found clear differences regarding the
publication and impact for the main medical fields
(number of trials ≥39). The high proportion of guide-
lines in psychiatry and psychotherapy, cardiovascular
Fig. 8 Impact on clinical practice. Total number of trials, published articles and systematic reviews (SRs) and guidelines, citing the
published articles
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disease and neurology is related to a high proportion of
publications and systematic reviews for these fields
(Fig. 11). When publication is low, this results in fewer
reviews and guidelines (ophthalmology, surgery).
Discussion
In the current project we assessed the research im-
pact on clinical practice of publicly sponsored trials
and commercially sponsored trials conducted in
Germany in comparison to those conducted inter-
nationally. By using a prospective strategy that
followed the lifecycle of a defined set of trials from
their registration up to their inclusion in systematic
reviews and clinical guidelines, we have collected and
analyzed data not only for those trials that were ‘suc-
cessful’, but also for trials that were not published
and did not gain an impact on clinical practice. We
were also interested in trial characteristics that were
associated with impact. Systematic reviews have
shown that several study factors are associated with
publication of clinical trial results, e.g. direction of
study findings, study size and duration [4, 31]. Those
factors could also have an influence on the impact
measures that go beyond publication, and also study
characteristics such as phase of clinical research
(study phase), medical field, type of funding or spon-
sorship, and place of conduct (country of study sites)
could play a role. An increased awareness of the risk
factors could improve the feasibility and efficiency of
future trials and the validity of trial results. Trials at
high risk of having no impact could be adjusted be-
forehand to ensure a successful trial progress.
Fig. 9 Publication and impact of trials
Fig. 10 Impact of trials per sub-cohort
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Interpretation of findings
We compared IITs with ISTs because they often focus
on different clinical questions and pursue different aims
and objectives. IITs play a crucial role in academic clin-
ical research whereas ISTs usually focus on commercial
interests, mainly of pharmaceutical companies, whose
primary aim is to develop and approve drugs or other
medical treatments [32]. In IITs, an academic investiga-
tor is responsible for the conduct of the clinical trial,
which includes planning, registration and publishing the
results of the study [33]. IITs are often conducted to ex-
pand product knowledge, including safety, and to iden-
tify new ways of using existing treatments, which might
lead to the improvement of patient health [34]. IITs
complement ISTs regarding the medical field, such as
physio- and psychotherapy, behavioral changes as well as
complementary medicine.
Compared to previous research, in our project a high
proportion of trials (83%) were published. Systematic re-
views and retrospective research projects investigating
the publication proportion of RCTs resulted in consider-
ably lower proportions of 60 to 71% [4, 35–37]. Only
37% of RCTs presented as conference abstracts were
published in full as journal articles [5]. The relatively
high proportion of published trials and trial results in
our cohort can be attributed to the fact that we also con-
sidered a trial as published, when its results were re-
ported in a study registry. Results in registries were also
considered in a recently published project that investi-
gated the publication proportion of trials conducted at
German university medical centers. Also in this project,
a publication proportion of 83% for completed trials
could be shown [38]. Subgroup analyses of this project
also confirmed our results, that larger trials are more
often published than smaller trials. A relatively high
publication proportion of 73% was also found for com-
pleted academic drug trials approved by the Danish
Medicines Agency [39]. However, academic trials ap-
proved by an Ethics committee in Spain had a consider-
able lower publication proportion of 39%, whereas 64%
of the commercially sponsored trials were published in a
peer-reviewed scientific journal [40]. For comparison,
the publication proportion of research projects beyond
clinical trials, e.g. basic research, funded by a medical
faculty in Germany, was 65% for publication in a peer-
reviewed journal, and 73% if also other publications were
counted [41].
Even though there are several advantages for posting
results in registries, e.g. results can be presented fast and
concisely, they are directly attached to the registry rec-
ord, and provide information about the trial methods as
well as references and links to further trial information,
the publication proportion is still relatively small. In a
cross sectional study across academic medical centers in
the United States, the publication proportion of com-
pleted trials that were registered in ClinicalTrials.gov
was analyzed. Across the medical centers, 10.8 to 40.3%
of the trials were published within 24 months of study
completion, and for 1.6 to 40.7%, results were reported
on ClinicalTrials.gov [42].
In our cohort, on average, for 45% (range of sub-
cohorts: 36–68%) of the trials we found results in study
registries. This finding is in line with the results of a re-
cent study, investigating the compliance with the Food
Fig. 11 Fate of trials per medical fields: surgery (S), psychiatry and psychotherapy (PP), cardiovascular disease (CD), endocrinology, diabetes, and
metabolism (EDM), Ophthalmology (O), respiratory system (RS), neurology (N)8
Blümle et al. BMC Medical Research Methodology          (2021) 21:182 Page 15 of 20
and Drug Administration Amendments Act of 2007
(FDAAA) concerning reporting of trial results. The re-
searchers found, that due to report results under the
FDAAA only about 40% of all applicable trials reported
their results in ClinicalTrials.gov within the 1 year dead-
line after study completion [43].
The possibility to add results to a study record in
registries, is certainly an important step to improve
transparency in clinical research. However, limited, in-
complete or expired trial information in registries often
make it difficult to get a complete picture of the trial
and to appraise and interpret the results. Several initia-
tives such as AllTrials and TranspariMed work on the
improvement of a trial’s reporting by requiring clinical
trials to be registered and to report their full methods
and summary results [14, 22].
In our cohort, of the trials with published results, 19%
(107 of 556) were solely available in study registries. This
has serious implications for the search process to iden-
tify relevant studies, i.e. which sources need to be
searched, especially for systematic reviews and clinical
guidelines. A search strategy should not only focus on
journal articles, but should be accomplished by an add-
itional search in study registries- This has already be-
come mandatory for conducting Cochrane intervention
reviews [44, 45]. To improve the findability of trial re-
sults, the registries themselves should improve their
searchability. They should be constructed in a standard-
ized format so that they are easily and reliably search-
able, e.g. similar to biomedical databases by title, author,
keywords and abstracts. Looking at our sub-cohorts, we
found a significant difference between IITs and ISTs.
For publicly sponsored trials, only 2–4% were solely
published in registries, whereas this was the case for 20
to 32% of the commercially sponsored trials. A similar
relation was found in a project investigating more than
30,000 clinical trials registered in the EU Clinical Trials
Register (EUCTR) [46]. Of those trials that were due,
which means that 12 months to publish the results had
passed, about 50% reported results in this register; 68%
of the commercial trials and only 11% of the non-
commercial trials. This higher proportion of results in
registries compared to our results could be explained by
the fact that in EUCTR only trials investigating medi-
cinal product are included and that for those trials dis-
closing of their results has been required by the
European Medicines Agency (EMA) since 2004. A
higher proportion of trials with results in registries were
also shown for clinical trials sponsored by the pharma-
ceutical industry trials compared to non-commercially
sponsored trials in Spain [40]. It must be noted that in
this project the commercial trials were registered signifi-
cantly more often in ClinicalTrials.gov than the aca-
demic trials.
The reasons for these observed differences are unclear
and future analyses would be worth to compare the
characteristics and results of those trials published solely
in registries with those published as journal articles, e.g.
regarding publication bias. One explanation could be
that for publicly funded trials publication of results in
the form of a journal article is often demanded by the
funding organization and is part of the funding condi-
tions. Advantages of publishing results as a journal art-
icle ideally are a quality-assured peer-review, trial
methods and results are considered and discussed in the
context of the existing evidence and can be commented
by other researches e. g. via response letters. For a great
proportion of trials in our cohort, results were published
as journal articles (81%), and for more than half of the
trials results were included in a registry.
Disclosure of detailed trial methods of a trial is essential
with respect to the critical appraisal and interpretation of
the results, and is the basis to enable other researchers to
reproduce the trial and verify its results, which is a basic
requirement for later implementation in medical practice.
While in an original journal research article both methods
and results of a trial are described, it is becoming more
common to publish articles only describing the detailed
methods of a trial and not the results. In our cohort, this
was the case for 14% of the trials, for 3% only a method
article could be identified. Moreover, it is important to
point out that most of the method articles derive from
publicly funded trials (87%), of which most of the German
IITs were from Public Germany gov (67%). In scientific re-
search it is not unusual to publish results of one study in
more than one article. One reason for this could be that in
academia the reward system is often built on quantity of
research output [47]. Scientific success, such as reputation,
career advancement, as well as successful applications for
research funding, is directly associated with the publica-
tion output of a researcher. In our project, multiple publi-
cation was the case for 188 (40%) trials. They were more
common for IITs (Germany: 33%, International: 32%) than
for ISTs (Germany: 17%, International 14%). The trial with
the highest number of identified publications (n = 21) was
a phase 4 study, conducted in the field of cardiovascular
disease, funded by the DFG. For this trial, one method
article, two result articles and 18 sub-studies and sec-
ondary analysis were published. This trial and also the
other high-frequently published trials (25 with more
than 5 published articles) were conducted in academia.
For this publication frequency, measured as the number
of published articles per trial, we found a remarkable
phenomenon: about one third of all published articles
corresponded to only 8 % of the trials. Even though this
aforementioned reward system and its consequences
have been in the focus of criticism for several years,
structures have still not changed [48].
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In contrast, in industry the main (financial) interest
lies in the results, i.e. efficacy and safety of the tested
treatment, whereas the study protocol and methods used
are often confidential to protect commercial interests.
This is also shown by the public availability of the study
protocols: for 40 trials of our cohort, the original study
protocol could be identified, 30 belonged to the IIT sub-
cohorts and 10 to the IST sub-cohorts.
A Health Technology Report was conducted to evalu-
ate the impact of Cochrane Reviews published by 20
Cochrane Review Groups, on health care, patient out-
comes and value for money [49]. Therefore, a random
sample of 20 Cochrane Reviews and 40 selected reviews,
more likely to have had an impact, were selected. Of the
60 included reviews, a considerable proportion of 67%
had been cited in clinical guidance and 15 had influ-
enced further primary research.
We found that more than half of the trials are repre-
sented in systematic reviews and more than a quarter in
guidelines. To further improve this knowledge transfer
from research into practice, several issues have to be
considered. The first issue is to understand, why 17% of
the trials have not been published. The second issue is
how to improve the transfer of the 28% of the trials that
were published but reached no impact.
Typical reasons for not publishing trial results as pre-
sented in a systematic review are lack of time and/or re-
sources, non-completion of study, publication was not
an aim, or only had low priority [50]. Further reasons
stated by sponsors of Danish academic clinical drug tri-
als were negative or not statistically significant results
[39]. Possible explanations for published trial results not
being included in systematic reviews are that no review
related to the research question has been conducted or
updated after the date of publication. Reasons reported
for non-inclusion of published articles in the systematic
reviews of our study cohort were that the eligibility cri-
teria were not fulfilled, e.g. wrong patient group, inter-
vention, comparator, outcome measure, or study type.
For inclusion of trial results in guidelines, the same
reasons as for systematic reviews could apply. However,
in guidelines, in addition to publications, systematic re-
views are also a relevant pathway for inclusion of trial
results. A detailed investigation of the systematic reviews
that have not been included in guidelines (56%) would
be useful, e.g. to find the reasons for lack of guidelines
and to be able to further improve the transfer of import-
ant trial findings into medical practice.
Strengths and limitations of the study
A strength of our study was that all trials were registered
in study registries so that for all of them basic study in-
formation was available. Study characteristics were
double-extracted independently in a pre-piloted
extraction form following a written manual. All data ex-
tractors were trained prior to the data extraction. We
captured all relevant information available in any study
registry. Discrepancies in different sources were dis-
cussed and resolved. The identification of systematic re-
views citing the original study report was conducted
semi-automatically by using a self-developed program.
The search for clinical guidelines was done manually fol-
lowing predefined standardized rules.
Another strength was that we controlled for possibly
biasing factors by design, i.e. by balancing important
study characteristics to Public Germany as the reference
sub-cohort.
A limitation arising from this was the limited number
of studies in the sub-cohorts Public Germany and Com-
mercial Germany. The number of trials meeting our in-
clusion criteria for the Public Germany gov (reference
sub-cohort) was fixed to 60. For the sub-cohort Com-
mercial Germany, a balancing for non-drug trials was
not fully possible: only 171 could be identified in DRKS
and ClinicalTrials.gov registries instead of the pre-
planned 200 studies per comparison sub-cohort. How-
ever, it is not expected that this difference of 29 trials
have a relevant influence on our results.
Our cohort was composed of trials that were included
in study registries and, partially, also in databases main-
tained by funding organizations. Against the background
that still not all trials are registered, our trial cohort
might be a “positive” selection compared to those con-
ducted worldwide. Therefore, there is a potential risk
that our cohort is biased, resulting in a limited external
validity of our project results.
Even though all studies were included in at least one
study registry, for some studies information in registries
was scarce and detailed study protocols were only rarely
available. Therefore, for some trials it was difficult to
find out whether a published article corresponded to the
trial. We also had to rely on the information reported in
registries. Data of prospectively registered studies can in-
clude preliminary study information, for example infor-
mation about study start and completion date. This may
have influenced our findings.
We tried to assess actual data and included trials that
started in 2005 or later and were completed by the end
of 2016, for which we searched for corresponding publi-
cations in 2018/2019. For trials completed late during
this time period, there might not have been sufficient
time for publication and inclusion in systematic reviews
and guidelines. Our results, however, indicate that this
only concerns a few trials because since 1) compared to
literature, the publication rate of our cohort was rela-
tively high, and 2) the stacked probability plot (Fig. 3)
also indicates that only few first publications are to be
expected. Nevertheless, in such projects there will always
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be a compromise between presenting actual data with
respect to the timeframe of included studies and leaving
enough time for studies to be published and have an
impact.
An important result of our study was that for 15% of
the trials, results were solely available in study registries
and were not published as journal article. In such cases,
we could only search for guidelines citing the trial by
using the registry identification number, but this was not
possible for systematic reviews. To identify citing sys-
tematic reviews, we used the “cited by”- or “times cited”-
functions of PubMed and WoS. These functions only
consider journal articles, so that we were limited to the
published journal articles.
The full text of some clinical practice guidelines from
the United Kingdom identified via NICE or TRIP were
only accessible to people located within the country, so
that we were not able to verify the citation for those.
Therefore, we did not consider them for our project.
Conclusion
To the best of our knowledge, our project provides the
first comprehensive and comparative evaluation of
investigator-initiated trials and industry-sponsored trials
with regard to their impact on clinical practice. It com-
prises not only publication of trial results in journals as
well as in study registries but also examines the different
factors that can be used as selective inclusion criteria of
results in systematic reviews, meta-analyses and clinical
guidelines. Previous investigations have focused on only
one aspect of clinical impact, mostly on the publication
of results. They also have been concentrated on a spe-
cific medical field or were based on studies conducted at
a single institution. An encouraging result of this project
is that with 83% a high proportion of clinical trials were
published, which is a significant improvement compared
to previous investigations. A reasonable percentage of
trials were used in systematic reviews (52%) as well as in
clinical guidelines (26%). IITs performed comparably or
not significantly worse than ISTs with respect to the
three IMPACT-aspects investigated. For publishing
study results, study registries have become an important
alternative or complement to journal articles. Neverthe-
less, there still were a certain proportion of trials that
were not published and/or had no impact which needs
to be decreased to increase the efficiency and to reduce
waste in medical research. As a first step, special atten-
tion could be given to smaller trials and non-drug trials,
which were significantly less often published or cited by
systematic reviews or clinical guidelines than larger trials
and non-drug trials. For statistical reasons, larger trials
had a higher probability to generate statistically signifi-
cant results. Nevertheless, trials with a smaller number
of participants, e.g. as is the case in early phase studies
or in case of limited scientific resources, are also justified
and should be available for inclusion in the total body of
evidence. Further research is needed to identify the rea-
sons and risk factors for non-publication or delayed pub-
lication of registered trials and for non-citation in
reviews and guidelines. A standardized reporting system,
implemented in the lifecycle of studies, that requests the
reasons in these cases could be an approach to reach
that goal. Such a system could also reveal, why published
results of commercial trials appear less often in reviews
and guidelines than academic trials.
Implications for policy, practice and research
Further efforts are needed to ensure that the results of
all trials conducted are published. Publication of all re-
sults of all trials should become mandatory, e.g. by legal
regulation and by requirement of funding organizations.
The proportion of published results of commercial trials
is comparable to those of academic trials, but they ap-
pear less often in reviews and guidelines. Further re-
search is needed to investigate the reasons for this
phenomenon. In this project, the only criterion for
measuring impact of trials on medical practice was in-
clusion or exclusion of their results. A more detailed
quantitative analysis of the “value” of their contribution
to the overall body of evidence and on medical practice
would be helpful to identify “valuable” trials. Considering
their study characteristics in the planning of future trials,
could increase the impact of clinical research. Specific-
ally for Germany, IITs funded by governmental bodies
reached an impact comparable to international IITs and
ISTs that is respectable. Thus, funding of high-quality
IITs by governmental bodies is worth the effort, should
be continued and further encouraged.
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